合并高危因素的妊娠糖尿病患者早期筛查和胰岛素强化干预的前瞻性研究

注册号:

Registration number:

ChiCTR-TRC-13003495 

最近更新日期:

Date of Last Refreshed on:

2016-02-27 20:39:57 

注册时间:

Date of Registration:

2013-02-20 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

合并高危因素的妊娠糖尿病患者早期筛查和胰岛素强化干预的前瞻性研究

Public title:

A prospective study of the risk factors of gestational diabetes in patients with early screening and intensive insulin intervention

注册题目简写:

English Acronym:

研究课题的正式科学名称:

合并高危因素的妊娠糖尿病患者早期筛查和胰岛素强化干预的前瞻性研究

Scientific title:

A prospective study of the risk factors of gestational diabetes in patients with early screening and intensive insulin intervention

研究课题代号(代码):

Study subject ID:

江苏省社会发展项目SBE201170735

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

魏琼 

研究负责人:

王少华 

Applicant:

Weiqiong 

Study leader:

Wang Shaohua 

申请注册联系人电话:

Applicant telephone:

+86 15850651365

研究负责人电话:

Study leader's
telephone:

+86 13701581801

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

weiqiong_seu@163.com

研究负责人电子邮件:

Study leader's E-mail:

wshgyj@yahoo.com.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京湖南路丁家桥87号,中大医院内分泌科

研究负责人通讯地址:

江苏省南京湖南路丁家桥87号,中大医院内分泌科

Applicant address:

87 Dingjiaqiao, Hunan Road, Nanjing, Jiangsu, China

Study leader's address:

87 Dingjiaqiao, Hunan Road, Nanjing, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

210009

研究负责人邮政编码:

Study leader's postcode:

210009

申请人所在单位:

东南大学附属中大医院内分泌科

Applicant's institution:

Lecturer of Department of Endocrine, Zhongda hospital, Southeast University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2012ZDllKY03.0

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

东南大学附属中大医院临床研究伦理委员会

Name of the ethic committee:

Approval Notice of IRB of Southeast University Zhongda Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2012-03-01 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

东南大学附属中大医院内分泌科

Primary sponsor:

Lecturer of Department of Endocrine, Zhongda hospital, Southeast University

研究实施负责(组长)单位地址:

江苏省南京湖南路丁家桥87号

Primary sponsor's address:

87 Dingjiaqiao, Hunan Road, Nanjing, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

江苏省社会发展项目 SBE201170735

Source(s) of funding:

Social development projects in Jiangsu province SBE201170735

研究疾病:

妊娠糖尿病  

Target disease:

Gestational diabetes

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究通过对合并GDM高危因素的我国妊娠妇女进行GDM早期筛查、有效的血糖管理及多种胰岛素干预方法的比较,评估母婴围产期并发症发生率及孕妇产后胰岛细胞功能、DM发生等一系列客观指标,旨在明确对上述人群进行GDM早期筛查的必要性、胰岛素强化干预治疗的安全性和有效性。为确立适合我国国情的上述GDM高危人群更优化治疗方案以确保其生殖健康和围产期安全提供可靠的临床研究依据。  

Objectives of Study:

The aim of study was to early screening, effective management of blood glucose, comparison of various insulin intervention and assessment of prenatal complication morbidity and postpartum islet cell function and incidence of diabetes in gestational diabetes risk population. Further, the study was to confirm the necessity of early screening, the safety and effectiveness of insulin intensive therapy, to establish optimize treatment regimens for China gestational diabetes risk population and ensure reproductive health and provide reliable clinical studies based on perinatal security.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

糖尿病酮症或酮症酸中毒、糖尿病高渗状态、糖尿病乳酸酸中毒等急性糖尿病并发症或严重慢性糖尿病并发症;合并先兆流产、妊高征、子痫等患者;充血性心力衰竭(NYHA分级Ⅲ~Ⅳ级);其他严重伴随疾病;谷氨酸脱羧酶(GAD)抗体阳性;高甘油三酯≥ 5.0mmol/L;有胰腺炎病史。

Exclusion criteria:

Diabetic ketosis or ketoacidosis, diabetic hyperosmolar state, diabetic lactic acidosis and other acute diabetes complications or serious chronic complications of diabetes, threatened abortion, pregnancy induced hypertension, eclampsia patients, congestive heart failure (NYHA class III-IV degrade) and other serious comorbidities, glutamic acid decarboxylase (GAD) antibodies positive; high triglycerides >=5.0mmol/L, pancreatitis dieases).

研究实施时间:

Study execute time:

From 2012-01-04 00:00:00 To 2013-01-09 00:00:00  

征募观察对象时间:

Recruiting time:

From 2012-03-22 00:00:00 To 2013-01-09 00:00:00

干预措施:

Interventions:

组别:

早期筛查组

样本量:

100

Group:

Early screening group

Sample size:

干预措施:

饮食运动控制,胰岛素

干预措施代码:

Intervention:

Diet motion control, insulin

Intervention code:

组别:

晚期筛查组

样本量:

100

Group:

Advanced screening group

Sample size:

干预措施:

胰岛素

干预措施代码:

Intervention:

insulin

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

南京市 

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

东南大学附属中大医院 

单位级别:

三级 

Institution
hospital:

Zhongda hospital, Southeast University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

HbA1c

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

口服葡萄糖耐量

指标类型:

次要指标

Outcome:

oral glucose tolerance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C肽

指标类型:

次要指标

Outcome:

C-peptide

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

LDL-C

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

LDL-C

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

triglycerides

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素

指标类型:

次要指标

Outcome:

insulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

稳态模型评估胰岛素抵抗指数

指标类型:

次要指标

Outcome:

HOMA-IR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均血糖值

指标类型:

次要指标

Outcome:

mean glucose value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均血糖水平

指标类型:

次要指标

Outcome:

MBG

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均血糖漂移幅度

指标类型:

次要指标

Outcome:

MAGE

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体质指数

指标类型:

次要指标

Outcome:

BMI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

餐后血糖漂移

指标类型:

次要指标

Outcome:

PPGE

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

收缩压

指标类型:

次要指标

Outcome:

SBP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

舒张压

指标类型:

次要指标

Outcome:

DBP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Apgar评分

指标类型:

次要指标

Outcome:

Apgar 5 mi

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

血液

Sample Name:

Blood

Tissue:

Blood

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 45 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

电脑随机

Randomization Procedure (please state who generates the random number sequence and by what method):

randomized numbers generated by the computer

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

东南大学附属中大医院内分泌科

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Lecturer of Department of Endocrine,,Zhongda hospital, Southeast University

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

东南大学附属中大医院内分泌科

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Lecturer of Department of Endocrine,,Zhongda hospital, Southeast University

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2013-08-19 00:00:00